Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 7 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter cialis original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

Microsoft word - ongoing ct medicine 2012 jul

CENTER FOR CLINICAL TRIALS
Ongoing Clinical Trials
DEPARTMENT OF MEDICINE (24)
Arthritis

TITLE : A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis
Or Rheumatoid Arthritis
Patients With Or At High Risk For Cardiovascular Disease Comparing
Celecoxib With Naproxen And Ibuprofen [PRECISION: Prospective Randomized Evaluation Of Celecoxib
Integrated Safety Vs. Ibuprofen Or Naproxen]
PROTOCOL NUMBER : A3191172
PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD
STUDY COORDINATOR : Irene Guna
CONTACT NUMBER : 09228372121
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00346216?term=A3191172&rank=1

TITLE
: A Phase IIB, 12 Week Radomized, Double-Blind, Parallel Group, Placebo-Controlled Study To
Evaluate Efficacy, Safety And Tolerability Of 2, 4 And 6 Mg Of Revamilast In Patients With Active
Rheumatoid Arthritis
Who Have Had An Inadequate Response To Methotrexate
PROTOCOL NUMBER : GRC 4039-203
PRINCIPAL INVESTIGATOR :
Juan Javier T. Lichauco, MD
STUDY COORDINATOR :
Irene Guna
CONTACT NUMBER
: 09228372121
For more details, click this link

http://www.clinicaltrials.gov/ct2/show/NCT01430507?term=GRC+4039-203&rank=1

TITLE
: A Randomized, Double-Blind, Parallel-Group, Phase 1 Study To Evaluate The Initial
Pharmacokinetics, Efficacy, And Safety Of CT-P13 Compared With Remicade When Co-Administered
With Methotrexate In Patients With Active Rheumatoid Arthritis
PROTOCOL NUMBER : CT-P13 1.2
PRINCIPAL INVESTIGATOR : Dr. Sandra V. Navarra, MD; Celltrion, Inc.
STUDY COORDINATOR : Irene Guna
CONTACT NUMBER
: 09228730601
For more details, call the number above.
TITLE : A Randomized, Double-Blind, Parallel-Group, Phase 3 Study To Demonstrate Equivalence In
Efficacy And Safety Of CT-P13 Compared With Remicade When Co-Administered With Methotrexate In
Patients With Active Rheumatoid Arthritis
PROTOCOL NUMBER : CT-P13 3.1
PRINCIPAL INVESTIGATOR : Sandra V. Navarra, MD
STUDY COORDINATOR : Irene Guna
CONTACT NUMBERS : 09228730601
For more details, call the number above.

TITLE : A Randomized, Double-Blind, Parallel Group Study Of The Safety And Effect On Clinical
Outcome Of Tocilizumab SC Versus Tocilizumab IV, In Combination With Traditional Disease Modifying
Anti-Rheumatic Drugs (Dmards), In Patients With Moderate To Severe Active Rheumatoid Arthritis
PROTOCOL NUMBER : WA22762
PRINCIPAL INVESTIGATOR : Juan J. Lichauco, MD
STUDY COORDINATOR : Irene Guna
CONTACT NUMBERS : 09228730601
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01194414?term=WA22762&rank=2
TITLE : A Two-Part, Phase 1 Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group
Study To Assess The Pharmacokinetics, Safety, And Tolerability Of MK-8808 And To Compare The
Pharmacokinetics Of MK-8808 With Rituximab (Mabthera™) In Patients With Rheumatoid Arthritis (RA)
PROTOCOL NUMBER : MK-8808 002
PRINCIPAL INVESTIGATOR : Paul V. Santos-Estrella, MD
STUDY COORDINATOR : N/A
CONTACT NUMBERS : 09228825441
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01390441?term=MK-8808+002&rank=1
TITLE : A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Of Secukinumab To
Demonstrate The Efficacy At 24 Weeks And To Assess The Long Term Safety, Tolerability And Efficacy
Up To 2 Years In Patients With Active Psoriatic Arthritis/ CAIN457F2306 (Phase III)
PROTOCOL NUMBER : CAIN457F2306
PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD
STUDY COORDINATOR : Irene Guña
CONTACT NUMBERS : 09228372121
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01392326?term=CAIN457F2306&rank=1
TITLE : A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial Of Golimumab, a Fully
Human Anti-TNF? Monoclonal Antibody, Administered Subcutaneously, In Methotrexate-Naive, Subjects
With Active Rheumatoid Arthritis (C054TO5)
PROTOCOL NUMBER : C054TO5
PRINCIPAL INVESTIGATOR : Juan Javier T. Lichauco, MD
STUDY COORDINATOR : Irene Guna
CONTACT NUMBERS : 09228372121
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00973479?term=anti-
TNF+golimumab&rank=8
Diabetes

TITLE : A Multicenter, International, Randomized, 2x2 Factorial Design Study To Evaluate The Effects Of
Lantus (Insulin Glargine) Vs Standard Care, And Of Omega-3 Fatty Acids Vs Placebo In Reducing
Cardiovascular Mortality In High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose
Tolerance (IGT), Or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Insulin
Glargine Intervention
PROTOCOL NUMBER : HOE901-4032
PRINCIPAL INVESTIGATOR : Ricardo E. Fernando, MD
STUDY COORDINATOR : Paz Figueroa
CONTACT NUMBER : 8595555
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00069784?term=origin%2C+insulin+glargine&rank=2
TITLE : A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel- Group, Multicenter Study
To Determine The Efficacy And Safety Of Albiglutide When Used In Combination With Metformin
Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, And Metformin Plus Placebo In
Subjects With Type 2 Diabetes Mellitus
PROTOCOL NUMBER : GLP112753
PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, MD
STUDY COORDINATOR : Cristobal Pesa
CONTACT NUMBERS : 09285047050
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00838903?term=112753&rank=1
TITLE : A Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study
To Determine The Efficacy And Safety Of Albiglutide Administered In Combination With Metformin And
Glimepiride Compared With Metformin Plus Glimepiride And Placebo And With Metformin Plus
Glimepiride And Pioglitazone In Subjects With Type 2 Diabetes Mellitus
PROTOCOL NUMBER : GLP112757
PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, MD
STUDY COORDINATOR : Cristobal Pesa
CONTACT NUMBERS : 09285047050
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00839527?term=albiglutide%2C+metformin%2Cglimepiride&rank=1
TITLE : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate Cardiovascular
Outcomes Following Treatment With Alogliptin In Addition To Standard Of Care In Subjects With Type 2
Diabetes And Acute Coronary Syndrome
(Phase 3b);
PROTOCOL NUMBER : (SYR-322_402)
PRINCIPAL INVESTIGATOR : Gabriel V. Jasul Jr, MD
STUDY COORDINATOR : Cristobal Pesa
CONTACT NUMBERS : 09285047050
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00968708?term=322_402&rank=1
TITLE : Asian Treat To Target Lantus Study: A Randomized, Multicentre, Multinational, Open-Label,
Parallel-Group, 24-Week Phase IV Study Evaluating The Effectiveness And Safety Of Physician Versus
Patient-Led Initiation And Titration Of Insulin Glargine In Type 2 Diabetes Mellitus (ATLAS Study)
PROTOCOL NUMBER : LANTU_R_04889
PRINCIPAL INVESTIGATOR : Roberto C. Mirasol, MD
STUDY COORDINATOR : Luna Reyes
CONTACT NUMBERS : 09176023414
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01169818?term=04889&rank=2
TITLE : A Phase III Randomised, Double-Blind, Active-Controlled Parallel Group Efficacy And Safety
Study Of BI 10773 Compared To Glimepiride Administered Orally During 104 Weeks In Patients With
Type 2 Diabetes Mellitus And Insufficient Glycaemic Control Despite Metformin Treatment
PROTOCOL NUMBER : BI 1245.28
PRINCIPAL INVESTIGATOR : Ricardo E. Fernando, MD
STUDY COORDINATOR : Alice Vega
CONTACT NUMBERS : 7230101 6336
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01167881?term=1245.28&rank=1
TITLE : A Multicenter, Randomized, Double-Blind, Active-Controlled Study To Evaluate The Durability Of
The Efficacy And Safety Of Alogliptin Compared To Glipizide When Used In Combination With Metformin
In Subjects With Type 2 Diabetes
PROTOCOL NUMBER : SYR-322_305
PRINCIPAL INVESTIGATOR : Elizabeth Ann Fernando-Catindig, MD
STUDY COORDINATOR : Levita C. Vitug
CONTACT NUMBERS : 7230101 6336
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT00856284?term=322_305&rank=1
TITLE : A Multinational, Multicenter, Post-Authorization, Prospective Observational Cohort Study To
Assess The Profile Of Vidagliptin And The Fixed-Dose Combination Of Vildagliptin/Metformin Relative To
Comparator Oral Anti-Diabetic Drugs In Patients With Type2 Diabetes In a Real-World Setting
PROTOCOL NUMBER : CLAF237A2403
PRINCIPAL INVESTIGATOR : Gabriel V. Jasul Jr., MD
STUDY COORDINATOR : Cristobal C. Pesa
CONTACT NUMBERS : 09286349420
For more details, click this link

http://www.clinicaltrials.gov/ct2/show/NCT00099866?term=profile+of+vildagliptin%2Fmetformin&rank=8

TITLE : An Observational, Multinational, Multi-Center Prospective Cohort Study To Assess Effectiveness,
Safety And Tolerability Of Treatment With Vildagliptin Or Single Pill Combination Of Vildagliptin/Metformin
In Type 2 Diabetes Mellitus In Real-World Setting/ GUARD Study
PROTOCOL NUMBER : CLAF237A-MAX-PH-01
PRINCIPAL INVESTIGATOR : Reynaldo F. Rosales, MD
STUDY COORDINATOR : Madonna Lozano
CONTACT NUMBERS : 09178592296
For more details, call the number above.
TITLE : A Multicentre, International, Randomised, Parallel Group, Double Blind Study To Evaluate
Cardiovascular Safety Of Linagliptin Versus Glimepiride In Patients With Type 2 Diabetes Mellitus At
High Cardiovascular Risk
PROTOCOL NUMBER : BI1218.74 / CAROLINA TRIAL
PRINCIPAL INVESTIGATOR : Gabriel V. Jasul, Jr., MD
STUDY COORDINATOR : Cristobal Pesa
CONTACT NUMBERS : 09285047050
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01243424?term=1218.74&rank=1
TITLE : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The
Efficacy And Safety Of Subcutaneous LY2127399 In Patients With Systemic Lupus Erythematosus
(SLE)

PROTOCOL NUMBER : H9B-MC-BCDS
PRINCIPAL INVESTIGATOR : Sandra V. Navarra, MD; Eli Lilly And Company
STUDY COORDINATOR : Irene Guna
CONTACT NUMBERS :
09228787381

For more details, click this link

http://www.clinicaltrials.gov/ct2/show/NCT01196091?term=H9B-MC-BCDS&rank=1
TITLE : Evaluation Of Chronic Kidney Disease Practice Pattern Through The Global Renal Information
Database (GRID) Project
PROTOCOL NUMBER : GRID-CKD Project
PRINCIPAL INVESTIGATOR : Benjamin A. Balmores, MD
STUDY COORDINATOR : N/A
CONTACT NUMBER : 7230101 4735
For more details, call the number above.
TITLE : A Post-Marketing Surveillance Study On The Effectiveness, Safety And Tolerability Of
Telbivudine (Sebivoâ®) 600 Mg Once Daily In The Treatment Of Chronic Hepatitis B Among Filipino
Patients
PROTOCOL NUMBER : CLDT600APH01
PRINCIPAL INVESTIGATOR : Randy Mercado, MD
STUDY COORDINATOR : N/A
CONTACT NUMBER : 8159371 loc.329
For more details, call the number above.

TITLE : Renvela® Post Marketing Surveillance Study In The Philippines Under The Modified Release
Program
PROTOCOL NUMBER : Renvela®
PRINCIPAL INVESTIGATOR : Benjamin A. Balmores, MD
STUDY COORDINATOR : N/A
CONTACT NUMBER : 7230101 6447
For more details, call the number above.

TITLE : A Descriptive Study Of The Efficacy And Safety Of ONGLYZA (Saxagliptin) Under Conditions
Of Actual Use In The Philippines
PROTOCOL NUMBER : D1680L0007
PRINCIPAL INVESTIGATOR : Michael L. Villa, MD
STUDY COORDINATOR : N/A
CONTACT NUMBER : 777 8805
For more details, click this link
http://www.clinicaltrials.gov/ct2/show/NCT01223456?term=onglyza+saxagliptin&rank=17
TITLE :
A Comparison Of Tuberculin Skin Test And Interferon-Gamma Release Assay Test Response In
Individuals With Strong Risk Factors For The Development Of Tuberculosis Due To Immune
Compromise
With The Same Response In Healthy Household Members Without Immune Compromise
PROTOCOL NUMBER : 242-11-222
PRINCIPAL INVESTIGATOR : Paul V. Santos Estrella, MD
STUDY COORDINATOR : Irene Guna
CONTACT NUMBER :09228825441
For more details, call the number above.

Source: http://rbd.stluke.com.ph/data/File/ongoing%20ct%20medicine%202012%20jul.pdf

securitymanagement.com

United States Court of Appeals FOR THE EIGHTH CIRCUIT Before HANSEN, Chief Judge,1 and McMILLIAN and BEAM, Circuit Judges. Strategic Directions Group, Inc. (SDG) appeals from a judgment of the districtcourt2 granting summary judgment in favor of Bristol-Myers Squibb Company(Bristol-Myers) in this trade secrets and breach of contract case. We affirm. 1The Honorable David R. Hansen became

Microsoft word - treatment options

Bladder Treatment Options Following an assessment with a competent healthcare practitioner, a treatment plan will be discussed and agreed with you, which may include any or all of the following: Fluid changes Recording the amount drunk and the volumes of urine produced can help to identify the optimum amount of fluid an individual requires. Considering the amount of caffeine intake

Copyright © 2010-2014 Pharmacy Pills Pdf